Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
You may also be interested in...
The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.
Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.
Emerging Company Profile: Based on discovery research at Yale, NextCure hopes S15 and other novel targets will provide new inroads in immuno-oncology, while much of the field remains focused on PD-1 inhibitors and combinations.